Vertex Pharmaceuticals price objective cut to $667 from $672
VRTX•BofA Global Research cut its price objective for Vertex Pharmaceuticals to $667 from $672.
Related News
The Hartford Insurance Group coverage initiated with hold rating and $137 price target
HIG•
Gray Media, St. Louis Blues strike multiyear deal for 10 over-the-air game simulcasts in 2026-27 season
GTN•
Sonoco Products Company: Truist Securities cuts target price to $62 from $68
SON•
IonQ reportedly to buy cybersecurity firm Elisity for up to $1.3 billion
IONQ•
Hamilton Lane partners with Chubb Wealth to offer private markets funds in Hong Kong
HLNE•